Scott Whitaker Op-Ed: Tariffs Should Spare Vital U.S. MedTech Industry
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
AdvaMed® Advancements: Q1 2025 Report
AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.
Accelerating Healthcare Solutions with B2B eCommerce
EPAM recently published a case study highlighting the rise of composable commerce solutions to enable B2B processes in the healthcare industry. This piece focuses on the experience of diagnostics company,…
State of the Nation 2025: Global Medical Device Recall Index Report
Download Sedgwick’s Global Medical Device Recall Report for key insights on compliance, regulations, and global recall trends. Members only.
The Medical Innovation Agenda for the 119th Congress
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Health Care Organizations on Concerns & Exemptions Regarding Tariffs
Tariffs on medical goods threaten healthcare costs, access, and supply chains. Leading health groups urge exemptions to safeguard patient care.
The Impact of Tariffs on Patient Access to Medical Technology
Tariffs on medtech could disrupt supply chains, increase costs, and delay care. Exemptions are needed to protect hospitals, patients, and innovation.
2024 Annual Report
Explore AdvaMed®’s key achievements and milestones in 2024 on behalf of our member companies and the patients they serve.